A unique and desirable combination, the deep, focal, and non-invasive nature of transcranial ultrasonic stimulation1 (TUS) has spurred growing interests in exploring its therapeutic potentials for neurological and neuropsychiatric diseases (e.g., stroke2, Parkinson's disease3, depression4, Alzheimer's disease5, etc.). Expert consensus and guidelines have sought to improve the reproducibility and interpretability of TUS research6,7. However, these primarily address the broader basic research applications of TUS and offer less guidance on exploring therapeutic relevance in humans. For example, when comparing basic and clinical TUS research, the total stimulation duration (TSD) differs substantially - often up to around 80 s in basic research8,9 versus over 10 min in exploratory protocols designed to approximate clinical use2. Such distinctions underscore the need for tailored guidance when exploratorily applying TUS to a neurologically diseased cohort. While this protocol focuses on TUS in stroke, its framework is broadly applicable to other patient populations, as well as neurotypical adults.
TUS delivers pressure waves to the target brain tissue for modulation7. Essential TUS hardware components include function generator(s), an amplifier, a transducer, and, especially for extended TSDs, an on-head transducer mount6. The function generator produces the electrical waveform that defines the exiting pressure pattern emitted by the transducer. While some function generators can generate the peak voltages required for TUS transducers, most require an amplifier to boost the signal between the function generator(s) and the transducer. The amplifier increases the amplitude of the electrical waveform to the level needed for effective ultrasound generation. Commercially available TUS systems often integrate the function generator and amplifier into a single turnkey unit, allowing direct connection to the transducer. The transducer, typically made of piezoelectric materials, converts the electrical signals into mechanical vibrations to produce ultrasound waves. Although manual transducer holding is possible, this approach is labor-intensive and susceptible to displacement errors, while a minor displacement can cause complete mistargeting of the intended tissue7. Mechanical arm with chin rest is also used and works well for basic research with relatively shorter TSDs. A feasible alternative for exploratory clinical TUS with TSDs over 10 min is 3D printing a transducer mount equipped with flanges for secure strap fixation (Figure 1), which can balance positional stability with ease of use in exploratory clinical settings and participant comfort.

Figure 1: 3D-printed mount for TUS transducer. Single-element transcranial ultrasonic stimulation (TUS) transducer (center piece pointed by the red arrow) housed in a 3D printed transducer mount (pointed by blue the arrow) with top openings (pointed by the green arrow) for neuronavigation's tool tracker, side openings (pointed by the brown arrow) to secure TUS transducer and tool tracker(s) using screws, and flanges for a strap-based on-head fixation. Please click here to view a larger version of this figure.
Optional hardware components include an electrical impedance matching circuit, a power meter, an oscilloscope, a neuronavigation system, and a thermocouple. These devices respectively aid in reducing electrical reflections to optimize power transfer, indirectly verifying acoustic outputs (power meter and oscilloscope), ensuring spatial accuracy, and monitoring safety. Their implementation details and methodological considerations are elaborated in the Discussion and the Protocol sections.
Optimizing the parameters of transcranial ultrasound stimulation is an active and evolving area of research, which pertains to the design of the electrical drive waveform. The vertical axis of a drive waveform determines the amplitude of transducer's pressure output. The horizontal axis of a drive waveform determines the timing of the transducer's pressure output, which can be broken down into a few duration and repetition types. Using the nomenclature outlined in the reporting guidelines by the International Transcranial Ultrasonic Stimulation Safety and Standards Consortium (ITRUSST)10, TUS timing parameters are organized from the shortest to the longest durations as follows: ramp duration (RD) is the time during which the pressure output ramps up from zero to the prescribed maximum; pulse duration (PD) is the duration for a single, active, and continuous pressure output; pulse repeat interval (PRI) is the duration between the beginning of two adjacent PDs, consisting of one PD and one "off time" during which the transducer output is zero, and the reciprocal of PRI is the pulse repetition frequency (PRF); pulse train duration (PTD) is the duration for which the PRI is repeated; pulse train interval (PTI) is the duration between the beginning of two adjacent PTDs, consisting of one PTD and one inter-PTD interval during which the transducer output is zero; pulse train repeat duration (PTRD) is the duration for which the PTI is repeated.

Figure 2: TUS waveform illustration. Typical transcranial ultrasonic stimulation waveforms for potential clinical efficacies. The nomenclature adheres to the ITRUSST reporting guidelines10. RD, ramp duration; PD, pulse duration; PRI, pulse repeat interval; PRF, pulse repetition frequency; PTD, pulse train duration; PTI, pulse train interval; PTRD, pulse train repeat duration. Please click here to view a larger version of this figure.
Figure 2 illustrates these timing parameters. Table 1.1 reports the timing parameters in Huang et al., 20252, from which this protocol is derived, in accordance with the tabular form recommended by the ITRUSST reporting guidelines10 while Table 1.2 reports additional parameters. Auditory effects are widely recognized as a major confound in TUS experiments6,11. Ramping the drive waveform is the most used method to mitigate auditory effects and thus will be considered the primary mitigation method in this protocol. Theoretically, distinct ramping profiles can be applied at the start and end of each active pressure output (i.e., PD, PTD, PTRD), but most studies employ a same symmetrical PD repeated throughout the entire stimulation session, resulting a single RD in the drive signal. Ramping is implemented using window functions, which define the "shape" and "speed" of the signal going from zero to the prescribed maximum, with the Tukey window being the most commonly used in the literature10. After controlling for auditory confounds, selecting parameters to elicit excitatory versus inhibitory effect remains an area of active research and depends on the specific experimental question. Parameter choices in Huang et al., 20252, from which this protocol is derived, were informed by existing literature12, with a PD decreased from 0.36 ms to 0.2 ms for additional safety margins. Methodological aspects were adapted from Legon et al., 201813. These selections are one detailed example rather than a prescriptive standard, reflecting the still-exploratory stage of clinical TUS. Consult the relevant literature for guidance tailored to study-specific hypothesis and objectives.
Transducer calibration is a critical consideration of TUS, and water tank scanning represents the most comprehensive method currently available. For non-turnkey TUS systems, an initial water tank scanning is strongly recommended to establish the transmitting sensitivity of the transducer, i.e., the relationship between the electrical drive voltage in Volts and the resulting pressure output in Pascals. Turnkey systems often come with vendor-preconfigured settings that may reduce the need for an initial calibration, but verifying the transducer output ensures accurate and high-quality TUS delivery. Similarly, although subsequent calibrations can be minimized if necessary, regular checks are advisable to enhance study rigor.
Performing water tank scanning generally requires specialist equipment and training. This protocol provides a brief overview in Step 2 (based on Chen et al., 202314). Alternatively, the procedure can be outsourced to a collaborative laboratory with the appropriate expertise with confirmation that all required parameters are collected (Step 2.7). Power meter measurements provide a simple, indirect method for measuring transducer output. After calibration or vendor characterization, power meter readings can serve as a benchmark for pre-administration output. Variation in power output implies corresponding changes in pressure outputs, indicating a need for either re-calibration or adjustment of the drive signal to maintain consistent stimulation.
TUS targeting involves determining the optimal transducer placement, both location and orientation, to effectively stimulate the tissue of interest. The current state-of-the-art approach employs numerical simulations to identify the optimal transducer placement (Step 3 of the protocol), though this represents one example rather than a definitive standard. Alternatively, an empirically based method previously reported locates the scalp location where transcranial magnetic stimulation (TMS) most effectively elicits contralateral motor responses, and positions the transducer at that location with its surface normal to the scalp2,3 (Step 4). In principle, this TMS-guided approach can be extended to other brain areas that have an identifiable output, such as the sight of phosphenes for the visual cortex. However, more data/publications are needed to validate the broader applicability of such approach.
Outcome measures for clinical TUS include both safety and efficacy-based assessments. Given the exploratory stage of clinical translation, pronounced efficacy may not yet be detectable using standard clinical measures. Therefore, surrogate response indicators are often used in place of efficacy measures to detect effects below clinical efficacy. Safety monitoring can incorporate both online and offline assessments. Online safety can be tracked using thermocouple(s) placed on the scalp during stimulation, offering a practical approach in the clinical setting (Step 6.5). For offline safety, this protocol provides instructions in apparent diffusion coefficient (ADC) quantification (Step 8), as ADC is commonly used to evaluate tissue integrity15. Surrogate response indicators vary depending on the targeted disease or domain of interest. For studies of post-stroke motor recovery, contralateral corticospinal excitability (CSE) and motor sequence learning (MSL) measures will be described (Steps 9-11) as they provide reliable neurophysiological and functional markers for the exploratory clinical efficacy of TUS.
Taken together, this protocol provides a detailed, modular, and adaptable example for administering TUS in both neurological and neurotypical adults, emphasizing ease of use and extended stimulation duration. The protocol is derived from Huang et al., 20252, which employs a non-turnkey drive system that allows customization of pulse shaping and single-element transducer. In a step-by-step manner, the system-agnostic general principle is presented first, and, where appropriate, system-specific example implementation is given.